Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIKARI: Certolizumab pegol monotherapy in Japanese RA patients
NCT00791921Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2008
- Primary completion
- Jan 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CDP870 200mg with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Nov 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00791921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791921.